Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU Basel, 5 May... Read more

CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)

If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU ENSPRYNG is the only subcutaneous treatment option for NMOSD that can be administered at home every four weeks Recommendation is based on results from the... Read more

Introducing ORG.one: a project to support rapid DNA sequencing of critically endangered species

Mon 19th April 2021 ORG.one is a pilot-stage project designed to support faster, more localised sequencing of critically endangered species, by enabling biologists to rapidly sequence those species close to the sample’s origin, using the latest ultra-long read approaches from Oxford Nanopore.​ Loss of biodiversity is an urgent problem. Genomics can help with existing conservation work, as well as securing the DNA sequence of... Read more

Roche provides update on tominersen programme in manifest Huntington’s disease

Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data Monitoring Committee (iDMC) No new safety signals were identified for tominersen in the iDMC’s review              Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1... Read more